17:33 , Jul 20, 2018 |  BC Week In Review  |  WIR Deals New Deals

Novartis in atopic dermatitis deal with MorphoSys, Galapagos

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to MOR106, a mAb against IL-17C that is in Phase II testing for atopic dermatitis. MorphoSys and Galapagos will...
20:37 , Jul 19, 2018 |  BC Extra  |  Company News

Novartis in atopic dermatitis deal with MorphoSys, Galapagos

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to MOR106, a mAb against IL-17C that is in Phase II testing for atopic dermatitis. MorphoSys and Galapagos will...
18:21 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Lilly's Taltz meets in Phase III for TNF inhibitor-experienced ankylosing spondylitis

Eli Lilly and Co. (NYSE:LLY) said Taltz ixekizumab met the primary endpoint of a greater proportion of patients achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) response at week 16 vs. placebo in the...
19:42 , May 18, 2018 |  BC Week In Review  |  Clinical News

Novartis to start head-to-head trial of Cosentyx and Tremfya

Novartis AG (NYSE:NVS; SIX:NOVN) plans to begin the head-to-head Phase IIa ARROW trial to compare Cosentyx secukinumab to Tremfya guselkumab for 16 weeks in 40 patients with Stelara ustekinumab-resistant plaque psoriasis. The pharma expects to...
17:43 , May 11, 2018 |  BC Week In Review  |  Clinical News

Lilly’s Taltz meets in Phase III for ankylosing spondylitis

In February, Eli Lilly and Co. (NYSE:LLY) reported top-line data from the Phase III COAST-V trial to treat axial spondyloarthritis showing that subcutaneous Taltz ixekizumab met the primary endpoint of a greater proportion of patients...
22:15 , Apr 24, 2018 |  BC Extra  |  Company News

Diabetes franchise drives 1Q18 for Lilly

Strong sales from the diabetes franchise of Eli Lilly and Co. (NYSE:LLY) led to 1Q18 results that outpaced consensus estimates. On Tuesday, the pharma reported revenue of $5.7 billion for the period, up 9% from...
21:45 , Apr 19, 2018 |  BC Extra  |  Company News

Novartis reports first Kymriah sales, Cosentyx miss

Novartis AG (NYSE:NVS; SIX:NOVN) reported $580 million in 1Q18 sales of autoimmune drug Cosentyx secukinumab, shy of analysts' $635 million consensus estimate. The pharma also reported for the first time sales of CAR T therapy...
20:58 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

Oxford BioDynamics reports data for predicting inadequate responders to methotrexate

Oxford BioDynamics plc (LSE:OBD) and colleagues reported that the presence of a five-marker Chromosome Confirmation Signature (CCS) in the blood of patients with early rheumatoid arthritis as detected by the company's EpiSwitch epigenetic biomarker platform...
02:44 , Mar 10, 2018 |  BioCentury  |  Product Development

Virtual leap

Novartis AG’s decision to expand a collaboration with mobile technology and clinical trials management company Science 37 Inc. fits squarely within CEO Vasant Narasimhan’s oft-stated plans to use digital health to speed drug development. The...
21:18 , Jan 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Dermatology

INDICATION: Dermatitis Mouse studies identified nine S. aureus and host factors as targets for treatment of dermatitis associated with S. aureus infections. In primary mouse and human keratinocytes treated with supernatants from S. aureus cultures, knockout...